cancer-research-structural-biochemistry-2019-tracks

Page 29

Volume 3

August 5-6, 2019 | Singapore

CANCER RESEARCH AND PHARMACOLOGY

STRUCTURAL BIOCHEMISTRY, STEM CELLS AND MOLECULAR BIOLOGY

International Conference on

International Congress on

Cancer Research 2019 & Structural Biochemistry 2019

August 5-6, 2019

Journal of Cancer and Metastasis Research

Enhanced targeting of chemotherapeutic drug to prostate cancer cells by antibody

conjugated polymeric nanoparticles

Iman Ehsan

Jadavpur University, India

rostate cancer has become common cause of cancer associated

mortality in males across the world. Prostate cancer is not perpetually

lethal, it is a heterogeneous disease ranging from asymptomatic to a

rapidly fatal systemic malignancy. Although recent advancement has

been made in the field of prostate cancer therapy, but low survival rates

persist among patients due to metastatasis, drug toxicity/ resistance and

high rates of recurrence. In recent years, polymeric nanoparticles have

demonstrated marked progress in the field of oncology. Polymeric

nanoparticles are widely used in tumor targeting as they possess ability to

shrink and eliminate tumors without damaging healthy tissue, overcoming

the lacunas of drug such as poor solubility, oral bioavailability and low therapeutic indices. An increased site specificity and

internalization was obtained by conjugating specific antibody to the nanoparticles to improve the efficacy of treatment of prostate

cancer and decrease the possibility of the serious side effects that cancer patients often experience. Biodegradable nanoparticles

(NP) containing an anti-cancer drug was prepared and tagged with anti-PSMA monoclonal antibody as an active targeting to

prostate cancer because anti-PSMAmonoclonal antibody recognizes and binds with the PSMAon the surfaces of prostate. PSMA

is prostate specific membrane antigen, a transmembrane receptor whose expression is largely restricted to prostatic epithelium

and prostate cancer cells with its expression level increasing during the progression of malignancy, the drug was released from

the nanoparticles leading to cell death. Pre-formulation studies such as drug excipient interaction studies, followed by preparation

and optimization of the NP were carried out and characterized for physiochemical characterization such as particle size, zeta

potential, morphology, drug loading capacity, drug encapsulation,

in vitro

drug release from NP was performed. Confirmatory

studies to determine the presence of the antibody on the surface of NP was evaluated. Storage stability study was conducted. The

NP and conjugated NP were utilized to evaluate its efficacy in the cellular uptake, quantification of it, cell viability, apoptosis in

the prostate cancer cells (PC3, LNCaP cell lines). Biodistribution and pharmacokinetic analysis were carried. Therefore, antibody

conjugated nanoparticle based therapy represents a novel approach to eliminate prostate cancer cells and is a promising potential

treatment strategy and may lead to development of prostate cancer model by xenograft model in mice.

Biography

Iman Ehsan is currently pursuing her PhD in Jadavpur University, India. She is working on novel drug delivery, her current area of

research is nanoformulations for site specific targeting of prostate and liver cancer. She has completed her M.Pharm from West Bengal

University of Technology, Kolkata, West Bengal, India.